Wealth Enhancement Advisory Services’s abrdn Life Sciences Investors HQL Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$217K	Sell	10,686 -1	-0%	-$18	﹤0.01%	3510
2026 Q1	$180K	Buy	+10,687	New	+$179K	﹤0.01%	3170
2024 Q4	–	Sell	-15,932	Closed	-$240K	–	3030
2024 Q3	$240K	Sell	15,932 -3,851	-19%	-$58.3K	﹤0.01%	2332
2024 Q2	$280K	Sell	19,783 -661	-3%	-$8.94K	﹤0.01%	2030
2024 Q1	$279K	Buy	20,444 +991	+5%	+$13.7K	﹤0.01%	1973
2023 Q4	$262K	Sell	19,453 -1,427	-7%	-$17.6K	﹤0.01%	1907
2023 Q3	$260K	Buy	+20,880	New	+$275K	﹤0.01%	1829

Other funds holding HQL

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Wealth Enhancement Advisory Services's HQL Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its abrdn Life Sciences Investors (HQL) stake by 0.01% in Q2 2026, selling an estimated $18 and leaving 10,686 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #3510.

Wealth Enhancement Advisory Services first reported a position in HQL in Q3 2023 and has held it in 7 quarters since. The position peaked at $280K in Q2 2024. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

Wealth Enhancement Advisory Services held 10,686 shares of abrdn Life Sciences Investors worth $217K as of Q2 2026.
Wealth Enhancement Advisory Services sold 1 abrdn Life Sciences Investors share in Q2 2026, an estimated $18.
abrdn Life Sciences Investors made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3510 holding.
Wealth Enhancement Advisory Services first reported a position in abrdn Life Sciences Investors in Q3 2023 and has held it in 7 quarters since.
Wealth Enhancement Advisory Services's abrdn Life Sciences Investors position peaked at $280K in Q2 2024.
83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.